Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Robbins

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Annals of the New York Academy of Sciences|April 20, 2005
Future vaccine development at NICHDJohn B Robbins, Rachel Schneerson
Lancet (London, England)|September 21, 2002
Pertussis in developed countriesJohn B Robbins, Rachel Schneerson, Birger Trollfors
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Surveillance for bacterial meningitis by means of polymerase chain reactionJohn B Robbins, Rachel Schneerson, Emil C Gotschlich
Infection and Immunity|August 23, 2003
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in miceZhigang Jin, Chiayung Chu, John B Robbins, et al.
The Journal of Clinical Investigation|July 18, 2002
Development of an improved vaccine for anthraxStephen H Leppla, John B Robbins, Rachel Schneerson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2007
Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in miceVince Pozsgay, Joanna Kubler-Kielb, Rachel Schneerson, et al.
American Heart Journal|April 13, 2004
Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccinesJohn B Robbins, Rachel Schneerson, Gary Horwith, et al.
The Journal of Infectious Diseases|January 21, 2006
Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old childrenAmina Ahmed, Jianpin Li, Yossi Shiloach, et al.
Infection and Immunity|March 14, 2007
Haemophilus influenzae type a infection and its preventionZhigang Jin, Sandra Romero-Steiner, George M Carlone, et al.
The Pediatric Infectious Disease Journal|May 7, 2005
Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccineBo A Claesson, Birger Trollfors, Teresa Lagergård, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Annals of the New York Academy of Sciences|April 20, 2005
Future vaccine development at NICHDJohn B Robbins, Rachel Schneerson
Lancet (London, England)|September 21, 2002
Pertussis in developed countriesJohn B Robbins, Rachel Schneerson, Birger Trollfors
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2004
Surveillance for bacterial meningitis by means of polymerase chain reactionJohn B Robbins, Rachel Schneerson, Emil C Gotschlich
Infection and Immunity|August 23, 2003
Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in miceZhigang Jin, Chiayung Chu, John B Robbins, et al.
The Journal of Clinical Investigation|July 18, 2002
Development of an improved vaccine for anthraxStephen H Leppla, John B Robbins, Rachel Schneerson, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2007
Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in miceVince Pozsgay, Joanna Kubler-Kielb, Rachel Schneerson, et al.
American Heart Journal|April 13, 2004
Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccinesJohn B Robbins, Rachel Schneerson, Gary Horwith, et al.
The Journal of Infectious Diseases|January 21, 2006
Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old childrenAmina Ahmed, Jianpin Li, Yossi Shiloach, et al.
Infection and Immunity|March 14, 2007
Haemophilus influenzae type a infection and its preventionZhigang Jin, Sandra Romero-Steiner, George M Carlone, et al.
The Pediatric Infectious Disease Journal|May 7, 2005
Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccineBo A Claesson, Birger Trollfors, Teresa Lagergård, et al.
Pageof 6